Abingdon represents a new philosophy, a first in class Drug Development Management Organization (DDMO) offering technical and operational expertise in all aspects of drug development from strategic assistance with candidate selection through pre-clinical and clinical portfolio development incorporating guidance on the strategy and minimum requirements for new drug applications including ANDAs and 505(b)2 applications.
 
Our Management Team has considerable expertise and success in selecting successful strategies for IND submission and implementation as well as extensive experience in clinical trial management and NDA/MAA submissions. Our experience covers a broad range of therapeutic areas and includes oncology, cardiovascular disease, endocrinology and metabolism, gastroenterology and infectious diseases.